Advances in pharmacotherapy for pediatric anxiety disorders
β Scribed by Moira Rynn; Anthony Puliafico; Charlotte Heleniak; Pranav Rikhi; Kareem Ghalib; Hilary Vidair
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 138 KB
- Volume
- 28
- Category
- Article
- ISSN
- 1091-4269
- DOI
- 10.1002/da.20769
No coin nor oath required. For personal study only.
β¦ Synopsis
Pediatric anxiety disorders are prevalent, chronic, and often lead to significant impaired functioning that impacts both short-and long-term outcomes for children and adolescents. Treatment options include pharmacotherapy and psychosocial interventions. This presentation will review treatment advances specifically for pharmacotherapy. Current research supports serotonin reuptake inhibitors as the medication class to be the first-line treatment option for pediatric anxiety disorders. Available evidence for the efficacy of other classes of medications will be reviewed, along with the available approaches to manage partial responders and nonresponders. The risks and benefits of pharmacotherapy will also be reviewed. In addition, recent research has shown the potential promise of novel agents that act upon other neural systems implicated in the development of pediatric anxiety disorders. Novel compounds that affect the glutamate system will be discussed. Depression and Anxiety 28:76-87, 2011.
π SIMILAR VOLUMES
## Abstract Pharmacotherapy is an effective part of treatment for most anxiety disorders, but not for specific phobia or performance anxiety. In them it is contraindicated, because it interferes with the effectiveness of exposure therapies and the extinction of fear responses. Interference with exp
A selection of articles that focus on psychosocial treatments, pharmacotherapy, and psychosurgery of anxiety disorders are reviewed. While some medications look clearly beneficial or potentially effective in the treatment of anxiety disorders, other compounds seem less promising or not effective. A
## Abstract Anxiety disorders are a highly prevalent and disabling class of psychiatric disorders. This review focuses on new directions in neurobiological research and implications for the development of novel psychopharmacological treatments. Neuroanatomical and neuroimaging research in anxiety d